{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:52:30Z","timestamp":1778111550920,"version":"3.51.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few randomized trials have compared therapies in mantle cell lymphoma (MCL), and the role of aggressive induction is unclear. The National Comprehensive Cancer Network (NCCN) Non-Hodgkin Lymphoma (NHL) Database, a prospective cohort study collecting clinical, treatment, and outcome data at 7 NCCN centers, provides a unique opportunity to compare the effectiveness of initial therapies in MCL. Patients younger than 65 diagnosed between 2000 and 2008 were included if they received RHCVAD (rituximab fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone), RCHOP+HDT\/ASCR (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + high-dose therapy\/autologous stem cell rescue), RHCVAD+HDT\/ASCR, or RCHOP. Clinical parameters were similar for patients treated with RHCVAD (n = 83, 50%), RCHOP+HDT\/ASCR (n = 34, 20%), RCHOP (n = 29, 17%), or RHCVAD+HDT\/ASCR (n = 21, 13%). Overall, 70 (42%) of the 167 patients progressed and 25 (15%) expired with a median follow-up of 33 months. There was no difference in progression-free survival (PFS) between aggressive regimens (P &gt; .57), which all demonstrated superior PFS compared with RCHOP (P &lt; .004). There was no difference in overall survival (OS) between the RHCVAD and RCHOP+HDT\/ASCR (P = .98). RCHOP was inferior to RHCVAD and RCHOP+HDT\/ASCR, which had similar PFS and OS. Despite aggressive regimens, the median PFS was 3 to 4 years. Future trials should focus on novel agents rather than comparing current approaches.<\/jats:p>","DOI":"10.1182\/blood-2011-07-369629","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T01:21:56Z","timestamp":1326244916000},"page":"2093-2099","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":85,"title":["Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database"],"prefix":"10.1182","volume":"119","author":[{"given":"Ann S.","family":"LaCasce","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Vandergrift","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network, Fort Washington, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Abel","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison L.","family":"Crosby","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auayporn P.","family":"Nademanee","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Blayney","sequence":"additional","affiliation":[{"name":"Stanford Cancer Center, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Millenson","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Vanderplas","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Lepisto","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network, Fort Washington, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Niland","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center, University of Rochester, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111808004282600_B1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111808004282600_B2","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808004282600_B3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111808004282600_B4","unstructured":"National Comprehensive Cancer Network Inc NCCN Non Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology. NCCN Web site 2010 Accessed May 18, 2010 http:\/\/www.nccn.org"},{"issue":"28","key":"2019111808004282600_B5","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"36","key":"2019111808004282600_B6","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808004282600_B7","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111808004282600_B8","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111808004282600_B9","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1002\/cncr.23911","article-title":"Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database.","volume":"113","author":"Kho","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"2019111808004282600_B10","first-page":"987","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project.","volume":"329","author":"A predictive model for aggressive non-Hodgkin's lymphoma","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111808004282600_B11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"2","key":"2019111808004282600_B12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111808004282600_B13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111808004282600_B14","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111808004282600_B15","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111808004282600_B16","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111808004282600_B17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma.","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808004282600_B18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.","volume":"19","author":"Martin","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111808004282600_B19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.V110.11.387.387","article-title":"A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma.","volume":"110","author":"Epner","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2019111808004282600_B20","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle Cell Lymphoma International Prognostic Index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.","volume":"29","author":"Budde","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111808004282600_B21","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [abstract].","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111808004282600_B22","article-title":"R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma [abstract].","volume":"118","author":"Kluin-Nelemans","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts). Blood"},{"key":"2019111808004282600_B23","article-title":"Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics","author":"FDA","year":"2007","journal-title":"Food and Drug Administration Web site"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/9\/2093\/1497856\/zh800912002093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/9\/2093\/1497856\/zh800912002093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T14:31:50Z","timestamp":1713364310000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/9\/2093\/30228\/Comparative-outcome-of-initial-therapy-for-younger"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-369629","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,1]]}}}